drugset
drugset / Trial / NCT04514237

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects

NCT04514237 ↗

Phase 1 Completed 12 enrolled Boston Pharmaceuticals
RandomizedSequentialTriple-blindBasic science

Summary

Part 1 of the study evaluates the safety and tolerability as well as pharmacokinetic properties of a single oral dose of BOS172767 enantiomer E1 and BOS172767 enantiomer E2 following administration to healthy participants. Part 2 of the study was to be conducted to assess the safety and tolerability as well as pharmacokinetic properties of one selected enantiomer (BOS172767-Ex) following multiple ascending doses over 14 days of dosing in healthy participants.

Timeline

Start
2019-09-12
Primary completion
2020-01-22
Completion
2020-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject BOS172767 enantiomer E1 Unknown 50 mg Oral
Subject BOS172767 enantiomer E1 or E2 Unknown 50 mg Oral

Indications

No indication recorded.